Cargando...
Biological challenges of BRAF inhibitor therapy
Activating mutations in BRAF, a constituent of the map kinase pathway, were first discovered as being most prevalent in melanoma in 2002. Only recently have potent and selective, orally available inhibitors of BRAF emerged for clinical testing and demonstrated clear evidence of tumor regression in t...
Guardado en:
| Publicado en: | Mol Oncol |
|---|---|
| Autores principales: | , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
John Wiley and Sons Inc.
2011
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5528282/ https://ncbi.nlm.nih.gov/pubmed/21393075 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2011.01.005 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|